Sumit Verma currently serves as Senior Vice President Global Strategy and Manufacturing for Iovance Biotherapeutics – an immuno-oncology company that is pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. He has executive responsibilities for building a new cell therapy manufacturing facility, the Iovance Cell Therapy Center (iCTC), in The Navy Yard Philadelphia. He also formed the commercial manufacturing organization at iCTC that will be involved in providing novel cancer cell therapies across North America and Europe.
Verma has successfully led commercial manufacturing teams in four new FDA-approved drug launches over the past 15 years. Prior to Iovance, he has had multiple leadership roles at Merck, Covidien, Mallinckrodt and most recently served as the Chief Operating Officer for Curium Pharmaceuticals. Sumit received his Bachelor of Science in Chemical Engineering from Lafayette College and Master’s in Engineering Management from Washington University in St. Louis
